This Article Full Text Full Text (PDF) All Versions of this Article: 46/4/660    most recent 01.HYP.0000179575.13739.72v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olsen, M. H. Articles by Hildebrandt, P. Search for Related Content PubMed PubMed Citation Articles by Olsen, M. H. Articles by Hildebrandt, P. Related Collections Risk Factors Epidemiology

(Hypertension. 2005;46:660.)
© 2005 American Heart Association, Inc.

Original Articles

N-Terminal Pro Brain Natriuretic Peptide Is Inversely Related to Metabolic Cardiovascular Risk Factors and the Metabolic Syndrome

Michael H. Olsen; Tine W. Hansen; Marina K. Christensen; Finn Gustafsson; Susanne Rasmussen; Kristian Wachtell; Knut Borch-Johnsen; Hans Ibsen; Torben Jørgensen; Per Hildebrandt

From the Research Center for Prevention and Health (M.H.O., T.W.H., S.R., T.J.), Glostrup University Hospital; Department of Cardiology (M.H.O., K.W.), Rigshospitalet; Department of Clinical Physiology and Nuclear Medicine (M.K.C.), Glostrup University Hospital; Department of Cardiology (F.G., P.H.), Frederiksberg University Hospital; Steno Diabetes Center (K.B.-J.), Gentofte; and Department of Internal Medicine (H.I.), Glostrup University Hospital, Denmark.

Correspondence to Dr Michael Hecht Olsen, Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, DK-2600 Glostrup, Denmark. E-mail mho{at}dadlnet.dk

We wanted to investigate the relationship of N-terminal pro brain natriuretic peptide (Nt-proBNP) to metabolic and hemodynamic cardiovascular (CV) risk factors in the general population. From a population-based sample of 2656 people 41, 51, 61, or 71 years of age, we selected 2070 patients without previous stroke or myocardial infarction who did not receive any CV, antidiabetic, or lipid-lowering treatment in 1993 to 1994. Traditional CV risk factors, 24-hour blood pressures, left ventricular (LV) mass, and ejection fraction by echocardiography, pulse wave velocity, urine albumin/creatinine ratio (UACR), and serum Nt-proBNP were measured in 1993 to 1994. The metabolic syndrome was defined in accordance with the definition of the European Group for the Study of Insulin Resistance (EGIR). Higher log(Nt-proBNP) was in multiple regression analysis related to female gender (ß=–0.37), older age (ß=0.32), higher clinic pulse pressure (ß=0.20), lower serum total cholesterol (ß=–0.15), lower LVEF (ß=–0.08, all P<0.001), lower log(serum insulin) (ß=–0.07), lower log(plasma glucose) (ß=–0.06, both P<0.01, lower log(serum triglyceride) (ß=–0.06), lower body mass index (ß=–0.05); lower heart rate (ß=–0.05), higher logUACR (ß=0.04, all P<0.05) and higher log(LV mass index) (ß=0.04, P=0.07), adjusted R²=0.35, P<0.001). The metabolic syndrome was associated with lower Nt-proBNP (35 pg/mL versus 48 pg/mL; P<0.001) and shifted the positive relationship between pulse pressure and Nt-proBNP to the right (ie, higher blood pressure for a given level of Nt-proBNP). The metabolic syndrome was associated with lower Nt-proBNP levels and shifted the positive relationship between Nt-proBNP and pulse pressure to the right, creating a possible link between the metabolic syndrome and hypertension.

Key Words: risk factors • albuminuria • hypertrophy • natriuretic peptides • obesity

This article has been cited by other articles:

				J. Ybarra, F. Planas, and J. M Pou Aminoterminal pro-brain natriuretic peptide (NT-proBNP) and sleep-disordered breathing in morbidly obese females: a cross-sectional study Diabetes and Vascular Disease Research, March 1, 2008; 5(1): 19 - 24. [Abstract] [PDF]

				M. Y. Rady B-Type Natriuretic Peptide and Sepsis: It Is Not Just the Heart J Intensive Care Med, November 1, 2007; 22(6): 386 - 388. [PDF]

				M. Schou, F. Gustafsson, C. N. Kistorp, P. Corell, A. Kjaer, and P. R. Hildebrandt Effects of Body Mass Index and Age on N-Terminal Pro Brain Natriuretic Peptide Are Associated with Glomerular Filtration Rate in Chronic Heart Failure Patients Clin. Chem., November 1, 2007; 53(11): 1928 - 1935. [Abstract] [Full Text] [PDF]

				E. Ingelsson, M. J. Pencina, G. H. Tofler, E. J. Benjamin, K. J. Lanier, P. F. Jacques, C. S. Fox, J. B. Meigs, D. Levy, M. G. Larson, et al. Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors: The Framingham Offspring Study Circulation, August 28, 2007; 116(9): 984 - 992. [Abstract] [Full Text] [PDF]

				A. M. Richards Natriuretic Peptides: Update on Peptide Release, Bioactivity, and Clinical Use Hypertension, July 1, 2007; 50(1): 25 - 30. [Full Text] [PDF]

				M. H. Olsen, T. W. Hansen, M. K. Christensen, F. Gustafsson, S. Rasmussen, K. Wachtell, H. Ibsen, C. Torp-Pedersen, and P. R. Hildebrandt N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population Eur. Heart J., June 1, 2007; 28(11): 1374 - 1381. [Abstract] [Full Text] [PDF]

				T. J. Wang, M. G. Larson, M. J. Keyes, D. Levy, E. J. Benjamin, and R. S. Vasan Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals Circulation, March 20, 2007; 115(11): 1345 - 1353. [Abstract] [Full Text] [PDF]